文献速递肝病

2型糖尿病患者中非酒精性脂肪性肝病与非酒精性脂肪性肝炎的全球流行病学

The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-03-21

该研究系统检索1990-2023年文献,纳入123项研究共2,224,144例2型糖尿病患者,采用随机效应模型进行Meta分析。结果显示,2型糖尿病患者中NAFLD/MASLD的全球合并患病率为65.33%(95%CI 62.35%-68.18%),NASH/MASH为66.44%(56.61%-75.02%),进展性纤维化为15.49%(6.99%-30.99%)。作者结论认为NAFLD/MASLD在2型糖尿病患者中患病率高且呈增长趋势。

要点

  • 2型糖尿病患者中NAFLD/MASLD全球合并患病率为65.33%(95%CI 62.35%-68.18%)。
  • 有肝活检数据的2型糖尿病患者中NASH/MASH患病率为66.44%(56.61%-75.02%)。
  • 全因死亡率为16.79/1000人年(95%CI 10.64-26.40)。

核心结论

  • 2型糖尿病患者中NAFLD/MASLD患病率高且呈增长趋势。
  • 多数NAFLD/MASLD合并2型糖尿病患者存在NASH/MASH,且相当比例有进展性纤维化。

研究设计与样本

  • 系统检索PubMed和Ovid MEDLINE中1990-2023年发表的NAFLD、NASH和T2D相关研究,按PRISMA进行。
  • 采用随机效应模型进行Meta分析,偏倚风险采用Joanna Briggs Institute评估工具。
  • 初检3134项研究,最终纳入123项研究(N=2,224,144例2型糖尿病患者)。
  • 另有12项研究(N=2733例有肝活检的2型糖尿病患者)纳入组织学评估。

主要发现

  • 2型糖尿病患者中NAFLD/MASLD全球合并患病率为65.33%(95%CI 62.35%-68.18%)。
  • NAFLD/MASLD患病率从1990-2004年的55.86%(42.38%-68.53%)升至2016-2021年的68.81%(63.41%-73.74%),P=.073。
  • 2型糖尿病患者中NAFLD/MASLD患病率以东欧最高(80.62%,75.72%-84.73%),其次为中東(71.24%,62.22%-78.84%),非洲最低(53.10%,26.05%-78.44%)。
  • 有肝活检数据者中,NASH/MASH、显著性纤维化和进展性纤维化的全球合并患病率分别为66.44%(56.61%-75.02%)、40.78%(24.24%-59.70%)和15.49%(6.99%-30.99%)。
  • 全因死亡率为16.79/1000人年(95%CI 10.64-26.40),心脏特异性死亡率为4.19/1000人年(1.34-7.05),肝外癌症特异性死亡率为6.10/1000人年(0.78-4.88),肝脏特异性死亡率为2.15/1000人年(0.00-2.21)。

局限性

  • NAFLD/MASLD患病率从1990-2004年到2016-2021年的增长趋势P=.073,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction associated steatotic liver disease (MASLD), is closely associated with type 2 diabetes (T2D). Our aim was to estimate the most recent global prevalence of NAFLD/MASLD, nonalcoholic steatohepatitis (NASH), now known as metabolic dysfunction associated steatohepatitis (MASH), advanced fibrosis, and mortality among patients with T2D. METHODS: We systematically searched PubMed and Ovid MEDLINE for terms including NAFLD, NASH, and T2D published in 1990-2023 according to PRISMA. The meta-analysis was conducted using a random-effects model. Assessment of bias risk used the Joanna Briggs Institute appraisal tool. RESULTS: From 3134 studies included in the initial search, 123 studies (N = 2,224,144 patients with T2D) were eligible. Another 12 studies (N = 2733 T2D patients with liver biopsy) were eligible for histologic assessments. The global pooled prevalence of NAFLD/MASLD among patients with T2D was 65.33% (95% confidence interval, 62.35%-68.18%). This prevalence increased from 55.86% (42.38%-68.53%) in 1990-2004 to 68.81% (63.41%-73.74%) in 2016-2021 (P = .073). The highest NAFLD/MASLD prevalence among T2D patients was observed in Eastern Europe (80.62%, 75.72%-84.73%), followed by the Middle East (71.24%, 62.22%-78.84%), and was lowest in Africa (53.10%, 26.05%-78.44%). Among patients with liver biopsy data, the global pooled prevalence of NASH/MASH, significant fibrosis, and advanced fibrosis was 66.44% (56.61%-75.02%), 40.78% (24.24%-59.70%), and 15.49% (6.99%-30.99%), respectively. The pooled all-cause mortality was 16.79 per 1000 person-years (PY) (10.64-26.40), 4.19 per 1000 PY (1.34-7.05) for cardiac-specific mortality; 6.10 per 1000 PY (0.78-4.88) for extrahepatic cancer-specific mortality; and 2.15 per 1000 PY (0.00-2.21) for liver-specific mortality. CONCLUSIONS: The prevalence of NAFLD/MASLD among T2D is high and growing. The majority of NAFLD/MASLD patients with T2D have NASH/MASH, and a significant proportion have advanced fibrosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Golabi P, Price JK, et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol. 2024. PMID: 38521116. doi:10.1016/j.cgh.2024.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。